3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene | 162012-34-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene
• 英文别名: 2,2,2-trifluoro-N-[4-[2-(4-fluorophenyl)thiophen-3-yl]phenyl]sulfonylacetamide
• CAS: 162012-34-2
• 化学式: C₁₈H₁₁F₄NO₃S₂
• 分子量: 429.416
• InChiKey: XZJGSVLJBHBKIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  99.9
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Prodrugs of COX-2 inhibitors
  申请人：——

  公开号：US20030055012A1

  公开（公告）日：2003-03-20

  A compound of Formula (I), or a pharmaceutically-acceptable salt thereof, suitable for use in the treatment of a cyclooxygenase-2 mediated disease is provided. 1 Also provided is a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically-acceptable salt thereof, and a method for treatment of a cyclooxygenase-2 mediated disease by administering to a subject in need thereof a therapeutically-effective amount of the pharmaceutical composition.

  提供一种符合以下式（I）的化合物，或其药用盐，适用于治疗环氧合酶-2介导的疾病。还提供了一种包含符合以下式（I）的化合物或其药用盐的药物组合物，以及通过向需要治疗的对象施用药物组合物的治疗有效量的方法，用于治疗环氧合酶-2介导的疾病。
• [EN] SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS<br/>[FR] DERIVES BENZENESULFONAMIDE SUBSTITUE UTILISABLES COMME PRECURSEURS DES INHIBITEURS DU COX-2
  申请人：G.D. SEARLE & CO.

  公开号：WO1997038986A1

  公开（公告）日：1997-10-23

  (EN) Prodrugs of COX-2 inhibitors of formula (I) are described as being useful in treating inflammation and inflammation-related disorders wherein A is a ring substituent selected from partially unsaturated heterocyclyl, heteroaryl, cycloalkenyl and aryl, wherein A is optionally substituted at a substitutable position with one or more radicals selected from alkylcarbonyl, formyl, halo, alkyl, haloalkyl, oxo, cyano, nitro, carboxyl, alkoxy, aminocarbonyl, alkoxycarbonyl, carboxyalkyl, cyanoalkyl, hydroxyalkyl, haloalkylsulfonyloxy, alkoxyalkyloxyalkyl, carboxyalkoxyalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocyclyloxy, alkylthio, cycloalkyl, aryl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl, and N-alkyl-N-arylaminosulfonyl; wherein R1 is selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; wherein R2 is selected from hydrido and alkoxycarbonylalkyl; and wherein R3 is selected from alkyl, carboxyalkyl, acyl, alkoxycarbonyl, heteroarylcarbonyl, alkoxycarbonylalkylcarbonyl, alkoxycarbonylcarbonyl, amino acid residue, and alkylcarbonylaminoalkylcarbonyl; provided A is not tetrazolium, or pyridinum; and further provided A is not indanone when R3 is alkyl or carboxyalkyl; or a pharmaceutically-acceptable salt thereof.(FR) La présente invention concerne des précurseurs, inhibiteurs du COX-2, représentés par la formule générale (I) et convenant en thérapie des inflammations et des troubles liés aux inflammations ou l'un de leurs sels galéniques. Dans cette formule générale (I), 'A' est un substituant cyclique appartenant au groupe des hétérocyclyle, hétéroaryle, cycloalkényle et aryle, la substitution de 'A' se faisant éventuellement en une position admettant la substitution, et ce, au moyen d'un ou plusieurs radicaux appartenant au groupe des alkylcarbonyl, formyl, halo, alkyl, haloalkyl, oxo, cyano, nitro, carboxyl, alcoxy, aminocarbonyl, alcoxycarbonyl, carboxyalkyl, cyanoalkyl, hydroxyalkyl, haloalkylsulfonyloxy, alcoxyalkyloxyalkyl, carboxyalcoxyalkyl, cycloalkylalkyl, alkényl, alkynyl, hétérocyclyloxy, alkylthio, cycloalkyl, aryl, hétérocyclyl, cycloalkényl, aralkyl, hétérocyclyalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, aralkényl, alcoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralcoxyalkyl, alcoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, alkylamino, N-arylamino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylaminoalkyl, aryloxy, aralcoxy, arylthio, aralkylthio, alkylsulfinyl,alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-aralkylaminosulfonyl, arylsulfonyl, et N-alkyl-N-arylaminosulfonyl; R1 appartient au groupe des hétérocyclyle, cycloalkyle, cycloalkényle et aryle, R1 étant éventuellement substitué, en une position admettant la substitution, au moyen d'un ou plusieurs radicaux appartenant au groupe des alkyl, haloalkyl, cyano, carboxyl, alcoxycarbonyl, hydroxyl, hydroxyalkyl, haloalcoxyn amino, alkylamino, arylamino, nitro, alcoxyalkyl, alkylsulfinyl, halo, alcoxy et alkylthio; R2 appartient au groupe des hydrido et alcoxycarbonylalkyl; et R3 appartient au groupe des alkyl, carboxyalkyl, acyl, alcoxycarbonyl, hétéroarylcarbonyl, alcoxycarbonylalkylcarbonyl, alcoxycarbonylcarbonyl, radical d'acide aminé et alkylcarbonylaminoalkylcarbonyl; 'A' ne devant être ni tétrazolium ni pyridinium; en outre 'A' ne peut être indanone lorsque R3 est alkyl ou carboxyalkyl.

  描述了公式（I）的COX-2抑制剂的前药在治疗炎症和与炎症相关的疾病中有用，其中A是从部分不饱和杂环基，杂环芳基，环烷基和芳基中选择的环取代基，其中A在可取代位置上可用一个或多个基团进行取代，所述基团从烷基羰基，甲酰基，卤素，烷基，卤素烷基，氧代，氰基，硝基，羧基，烷氧基，氨基羰基，烷氧羰基，羧基烷基，氰基烷基，羟基烷基，卤素烷磺酰氧基，烷氧烷氧基烷基，羧酸烷氧基烷基，环烷基烷基，烯烃基，炔基，杂环氧基，烷硫基，环烷基，芳基，杂环基，环烷基烯烃基，芳基烷基，烷硫基烷基，芳基羰基，芳基烷羰基，芳基烯基，烷氧基烷基，芳硫基烷基，芳氧基烷基，芳烷硫基烷基，芳氧基烷基，烷氧羰基烷基，氨基羰基烷基，烷基氨基羰基，N-芳基氨基羰基，N-烷基-N-芳基氨基羰基，烷基氨基羰基烷基，烷基氨基，N-芳基氨基，N-芳基烷基氨基，N-烷基-N-芳基氨基，N-烷基-N-芳基氨基，氨基烷基，烷基氨基烷基，N-芳基氨基烷基，N-芳基烷基氨基烷基，N-烷基-N-芳基氨基烷基，N-烷基-N-芳基氨基烷基，芳氧基，芳基氧基，芳硫基，芳烷硫基，烷基亚磺酰基，烷基磺酰基，氨基磺酰基，烷基氨基磺酰基，N-芳基氨基磺酰基，芳基磺酰基和N-烷基-N-芳基氨基磺酰基中选择；其中R1选择自杂环基，环烷基，环烷基烯烃基和芳基，其中R1在可取代位置上可用一个或多个基团进行取代，所述基团从烷基，卤素烷基，氰基，羧基烷氧基，羟基，羟基烷基，卤素烷氧基，氨基，烷基氨基，芳基氨基，硝基，烷氧基烷基，烷硫基，卤素，烷氧基和烷硫基中选择；其中R2选择自氢和烷氧羰基烷基；其中R3选择自烷基，羧基烷基，酰基，烷氧羰基，杂环芳基羰基，烷氧羰基烷基羰基，烷氧羰基羰基，氨基酸残基和烷基羰基氨基烷基羰基；前提是A不是四唑或吡啶，且当R3为烷基或羧基烷基时，A不是吲哚酮；或其药学上可接受的盐。
• [EN] PHENYL HETEROCYCLES AS COX-2 INHIBITORS<br/>[FR] HETEROCYCLES PHENYLIQUES UTILISES COMME INHIBITEURS DE COX-2
  申请人：MERCK FROSST CANADA INC.

  公开号：WO1995018799A1

  公开（公告）日：1995-07-13

  (EN) The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).(FR) L'invention se rapporte à un nouveau composé de la formule (I), utilisé dans le traitement des maladies induites par cyclooxygénase-2 (COX-2). L'invention se rapporte également à certaines compositions pharmaceutiques destinées au traitement des maladies induites par cyclooxygénase-2 et comprenant les composés de la formule (I).

  该发明涵盖了式（I）的新型化合物，用于治疗环氧合酶-2介导的疾病。该发明还涵盖了某些药物组合物，用于治疗环氧合酶-2介导的疾病，其中包括式（I）的化合物。
• Phenyl heterocycles as cyclooxygenase-2 inhibitors
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0822190A1

  公开（公告）日：1998-02-04

  The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  该发明涵盖了一种新的化合物I式，该化合物对于治疗环氧合酶-2介导的疾病具有用处。该发明还涵盖了某些药物组合物，用于治疗环氧合酶-2介导的疾病，该组合物包括I式化合物。
• Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
  申请人：Merck Frosst Canada Inc./Merck Frosst Canada & Co.

  公开号：US20010016595A1

  公开（公告）日：2001-08-23

  The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor. Although a wide range of COX-II inhibitors may be employed but it is preferred to employ compounds of the Formula I: 1

  本发明提供了一种治疗神经退行性疾病，尤其是阿尔茨海默病的方法，该方法包括向需要治疗的人类施用治疗有效量的非甾体COX-II抑制剂。虽然可以使用广泛的COX-II抑制剂，但最好使用I式化合物：1的化合物。